Supplementary Table S2: Laboratory Abnormalities from FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia

MLA

Richard Pazdur, et al. Supplementary Table S2: Laboratory Abnormalities from FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.22472652.v1.

APA

Richard Pazdur, Ann T. Farrell, Kirsten B. Goldberg, Ruby Leong, Chao Liu, Christopher M. Sheth, Yuan-Li Shen, Donna Przepiorka, Pedro L. Del Valle, Luning Zhuang, Sriram Subramaniam, Kunthel By, & Kelly J. Norsworthy. (2023). Supplementary Table S2: Laboratory Abnormalities from FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia. https://doi.org/10.1158/1078-0432.22472652.v1

Chicago

Richard Pazdur, Ann T. Farrell, Kirsten B. Goldberg, Ruby Leong, Chao Liu, Christopher M. Sheth, Yuan-Li Shen, et al. 2023. “Supplementary Table S2: Laboratory Abnormalities from FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia,” March. doi:10.1158/1078-0432.22472652.v1.